Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
131 Leser
Artikel bewerten:
(0)

Yorkshire Water Finance Plc - Publication of Final Terms

Finanznachrichten News

Yorkshire Water Finance Plc - Publication of Final Terms

PR Newswire

LONDON, United Kingdom, January 23

Yorkshire Water Finance plc

(a company incorporated in England with registered office at Western Way, Halifax Road, Bradford, BD6 2SZ and company number 11444372)

LEI: 213800O8BDOGHJMTCP32

Publication of Final Terms

The following Final Terms issued under the £8,000,000,000 multicurrency programme for the issuance of Guaranteed Bonds, with Yorkshire Water Finance plc as the issuer and Yorkshire Water Services Limited, Yorkshire Water Services Holdings Limited and Yorkshire Water Services Finance Limited as the guarantors (the "Programme") are available for viewing:

Final Terms dated 22 January 2025 for Yorkshire Water Finance plc's £50,000,000 Class A 5.250 per cent. Guaranteed Unwrapped Bonds due 28 April 2030 (to be consolidated and form a single series with the existing £250,000,000 Series 4 Class A 5.250 per cent. Guaranteed Unwrapped Bonds due 28 April 2030) (the "2030 Notes")

Final Terms dated 22 January 2025 for Yorkshire Water Finance plc's £100,000,000 Class A 6.375 per cent. Guaranteed Unwrapped Bonds due 18 November 2034 (to be consolidated and form a single Series with the existing £400,000,000 Series 6 Class A 6.375 per cent. Guaranteed Unwrapped Bonds due 18 November 2034) (the "2034 Notes")

Final Terms dated 22 January 2025 for Yorkshire Water Finance plc's £100,000,000 Class A 5.500 per cent. Guaranteed Unwrapped Bonds due 28 April 2035 (to be consolidated and form a single Series with the existing £275,000,000 Series 5 Class A 5.500 per cent. Guaranteed Unwrapped Bonds due 28 April 2035) (the "2035 Notes")

The Final Terms in respect of the 2030 Notes, the Final Terms in respect of the 2034 Notes and the Final Terms in respect of the 2035 Notes (together, the "January Final Terms"), respectively, should be read and construed in conjunction with the base prospectus dated 29 August 2024, as supplemented by a supplementary prospectus dated 17 January 2025, relating to the Programme (together, the "Prospectus").

2030 Notes:

To view the full Final Terms in respect of the 2030 Notes, please click the attachment.

2034 Notes:

To view the full Final Terms in respect of the 2034 Notes, please click the attachment.

2035 Notes:

To view the full Final Terms in respect of the 2035 Notes, please click the attachment.

Copies of the January Final Terms have been submitted to the National Storage Mechanism and will shortly be available for inspection at:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism

For further information, please contact:

Yorkshire Water

Western House

Halifax Road

Bradford

West Yorkshire

BD6 2SZ

Email: debtIR@keldagroup.com

Attention: Daniel Clarke

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in the January Final Terms may be addressed to and/or targeted at persons who are residents of particular countries (specified in the January Final Terms) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the January Final Terms is not addressed. Prior to relying on the information contained in the January Final Terms you must ascertain from the January Final Terms whether or not you are part of the intended addressees of the information contained therein.

In particular, the January Final Terms do not constitute an offer of securities for sale in the United States and are not for distribution in the United States. The January Final Terms have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state of the United States of America and are subject to U.S. tax law requirements. Subject to certain exceptions, securities issued under the Prospectus may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons or to persons within the United States of America, as such terms are defined in Regulation S under the Securities Act. There will be no public offering of the securities in the United States.

Your right to access this service is conditional upon complying with the above requirement.




YW - Final Terms 2030

YW - Final Terms 2034

YW - Final Terms 2035

© 2025 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.